FindTrial
Sign In

Soquelitinib

DRUG6 trials

Sponsors

Corvus Pharmaceuticals Inc., Corvus Pharmaceuticals, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Angioimmunoblastic T-cell LymphomaAtopic DermatitisAtopic Dermatitis EczemaAtopic dermatitis (AD)Autoimmune Lymphoproliferative SyndromeEczemaEczema, AtopicFollicular T-Cell Lymphoma

Phase 1

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD
CompletedNCT06345404
Corvus Pharmaceuticals, Inc.Atopic Dermatitis
Start: 2024-04-16End: 2026-02-24Updated: 2026-03-12
Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa
Not yet recruitingNCT07828860
Corvus Pharmaceuticals, Inc.Hidradenitis Suppurativa (HS)
Start: 2026-09-01End: 2027-12-01Target: 25Updated: 2026-09-18

Phase 2

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients
RecruitingNCT06730126
National Institute of Allergy and Infectious Diseases (NIAID)Autoimmune Lymphoproliferative Syndrome
Start: 2025-03-10End: 2026-12-01Target: 15Updated: 2026-09-08
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
RecruitingNCT07441395
Corvus Pharmaceuticals, Inc.Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema +1
Start: 2026-02-01End: 2027-09-01Target: 200Updated: 2026-03-05
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
Not yet recruitingCTIS2025-524384-20-00
Corvus Pharmaceuticals Inc.Atopic dermatitis (AD)
Target: 29Updated: 2026-09-18

Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingNCT06561048
Corvus Pharmaceuticals, Inc.Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Lymphoma, T-Cell +4
Start: 2024-10-02End: 2028-12-01Target: 150Updated: 2026-04-08

Related Papers

Final results of a phase 1 trial with soquelitinib (SQL), a selective interleukin-2-inducible T cell kinase (ITK) inhibitor for treatment of relapsed/refractory (R/R) T cell lymphomas (TCL)
Blood2025-11-03